Track Dynavax Technologies Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Dynavax Technologies Corporation DVAX Open Dynavax Technologies Corporation in new tab

15.50 USD
P/E
84.93
EPS
-0.37
P/B
3.41
ROE
-7.14
Beta
0.93
Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

🧾 Earnings Recap – Q3 2025

Dynavax Technologies delivered robust third quarter results, highlighted by a 13% year-over-year increase in net product revenue for HEPLISAV-B and strategic advancement in its clinical pipeline, including an exclusive license for a novel oral COVID-19 vaccine candidate.

  • HEPLISAV-B generated $90 million in net revenue, achieving a 46% market share in the U.S. adult hepatitis B vaccine market.
  • The company announced a new $100 million share repurchase program, reinforcing its commitment to shareholder value.
  • Dynavax entered into a strategic partnership with Vaxart for a Phase IIb COVID-19 oral vaccine candidate, targeting a significant unmet need in COVID-19 prevention.
  • Continued momentum in clinical pipeline advancement, with key developments in shingles and pandemic flu vaccine candidates underway.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 4, 2026
P/E84.93
EPS-0.37
Book Value4.55
Price to Book3.41
Debt/Equity54.15
% Insiders0.753%
Growth
Revenue Growth0.18%
Earnings Growth0.69%
Estimates
Forward P/E46.97
Forward EPS0.33

DCF Valuation

Tweak assumptions to recompute fair value for Dynavax Technologies Corporation (DVAX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Dynavax Technologies Corporation Logo Dynavax Technologies Corporation Analysis (DVAX)

United States Health Care Official Website Stock

Is Dynavax Technologies Corporation a good investment? Dynavax Technologies Corporation (DVAX) is currently trading at 15.50 USD.

In terms of valuation, the stock trades at a P/E ratio of 84.93. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Dynavax Technologies Corporation is expected to release its next earnings report on May 4, 2026. The market consensus estimate for Forward EPS is 0.33.

Investor FAQ

Does Dynavax Technologies Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Dynavax Technologies Corporation?

Dynavax Technologies Corporation is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 4, 2026. The company currently has a trailing EPS of -0.37.

Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Exchange Ticker
NMS (United States) DVAX
FRA (Germany) DYF1.F
LSE (United Kingdom) 0IDA.L

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Nov. 10, 2014 0.100000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion